Skip to main content
. Author manuscript; available in PMC: 2022 Feb 12.
Published in final edited form as: N Engl J Med. 2021 Aug 12;385(7):595–608. doi: 10.1056/NEJMoa2101016

Figure 1. Trial Design, Screening, Randomization, and Follow-up.

Figure 1.

CAB denotes cabotegravir, CAB-LA long-acting injectable CAB, HIV human immunodeficiency virus, PK pharmacokinetic, and TDF–FTC tenofovir disoproxil fumarate–emtricitabine.